Barrington analyst Michael Petusky lowered the firm’s price target on Anika Therapeutics (ANIK) to $15 from $19 and keeps an Outperform rating on the shares, citing “incrementally negative Hyalofast news” for the firm’s lowered target. However, shares are “meaningfully undervalued and trading near max skepticism after yesterday’s 27% decline,” the analyst argues.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIK: